{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:28:33Z","timestamp":1789021713688,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.humpath.2017.10.003","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T16:32:48Z","timestamp":1507998768000},"page":"49-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti\u2013PD-1\/PD-L1 therapy"],"prefix":"10.1016","volume":"70","author":[{"given":"Jordan A.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul S.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanjuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2017.10.003_bb0005","series-title":"WHO classification of tumours of the digestive system","author":"Bosman","year":"2010"},{"key":"10.1016\/j.humpath.2017.10.003_bb0010","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","author":"Sorbye","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2017.10.003_bb0015","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1245\/s10434-015-5013-2","article-title":"Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a Nordic multicenter comparative study","volume":"23","author":"Haugvik","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.humpath.2017.10.003_bb0020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.humpath.2017.10.003_bb0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2017.10.003_bb0030","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2017.10.003_bb0035","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","article-title":"Molecular pathways: next-generation immunotherapy\u2014inhibiting programmed death-ligand 1 and programmed death-1","volume":"18","author":"Chen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.10.003_bb0040","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-16-3146","article-title":"PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors","volume":"23","author":"Kluger","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.10.003_bb0045","doi-asserted-by":"crossref","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.humpath.2017.10.003_bb0050","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2017.10.003_bb0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/AJCP\/AQX070","article-title":"Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma?","volume":"148","author":"Thota","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2017.10.003_bb0060","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/gutjnl-2016-311421","article-title":"Tumour CD274 (PD-L1) expression and T cells in colorectal cancer","volume":"66","author":"Masugi","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.humpath.2017.10.003_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.humpath.2017.10.003_bb0070","doi-asserted-by":"crossref","first-page":"24644","DOI":"10.18632\/oncotarget.15602","article-title":"PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma","volume":"8","author":"Fontugne","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2017.10.003_bb0075","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2017.10.003_bb0080","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti\u2013PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2017.10.003_bb0085","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti\u2013PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2017.10.003_bb0090","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/2326-6066.CIR-15-0116","article-title":"PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells","volume":"3","author":"Mahoney","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817717303623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817717303623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T14:05:31Z","timestamp":1570197931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817717303623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":18,"alternative-id":["S0046817717303623"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2017.10.003","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti\u2013PD-1\/PD-L1 therapy","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}